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Abstract 
Background: Among all of the pediatric vaccinations recommended by the CDC, the 
HPV vaccination has consistently had lower adherence rates than the goal set by Healthy 
People 2020. The CDC recommends that adolescents start receiving the human 
papillomavirus (HPV) vaccine at the ages 9-11 to provide protection against certain strains of 
HPV that can cause cancer. The goal is to administer the HPV vaccine before the adolescent 
would be exposed to the virus. However, there has been much resistance and non-adherence 
to the HPV vaccination. Purpose: The purpose of this study was to identify the current rates 
of HPV vaccination in children ages 11 to 14 in the selected pediatric primary care clinic and 
examine provider-identified facilitators and barriers to HPV vaccination. Methods: This 
study incorporated a retrospective chart review and the use of an online survey sent to 
pediatric primary care providers that included qualitative and quantitative questions that 
pertained to HPV vaccination barriers and facilitators. Results: There were 100 randomly 
selected charts included in the retrospective chart review and 9 pediatric primary care 
providers voluntarily participated in the survey. Discussion: HPV vaccine rates have risen 
within the last decade, but there are still some improvements needed to achieve the goal rates 
of Healthy People 2020.  
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Background  
Human papillomavirus virus (HPV) is one of the most common sexually transmitted 
infections in the United States (U.S.) and a known cause in cancers of oropharyngeal, 
cervical, vulvar, cervical, penile and anal sites (Vollrath, Thul, & Holcombe, 2017). 
According to the Centers for Disease Control and Prevention (2017), about 79 million 
Americans are currently diagnosed with HPV and 14 million become newly diagnosed each 
year. There are approximately 19,400 women and 12,100 men that are affected by cancers 
that relate to HPV (Centers for Disease Control and Prevention, 2017). Fortunately, there is a 
capable vaccine that will aid in protection from certain strains of HPV, specifically those 
strains that are most commonly associated with cancer. The most effective time to administer 
and recommend this vaccine is to children around the age of 11 or 12 (Centers for Disease 
Control and Prevention, 2016). The HPV vaccine first made its debut about a decade ago and 
still presents as a challenge today for vaccine uptake in the recommended population 
(Vollrath, Thul, & Holcombe, 2017).  This challenge has been addressed by the Centers for 
Disease Control and Prevention and Healthy People 2020 with initiatives to help increase 
HPV vaccination rates.  
There is evidence that supports a decrease in HPV  prevalence since the HPV vaccine 
was licensed and recommended by the CDC eight years ago (Oliver, Unger, Lewis, 
McDaniel, Gargano, Steinau, & Markowitz, 2017). In the age group of 14-19 year olds, these 
HPV types decreased from 11.5% in 2003-2006 to 3.3% in 2011-2014 (Oliver, Unger, Lewis, 
McDaniel, Gargano, Steinau, & Markowitz, 2017). There is a constant battle with 
vaccination rates for children in the U.S., as none of the recommended vaccinations 
determined by the CDC have ideal coverage among children. However, the human 
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papillomavirus (HPV) vaccination, has one of the lowest vaccination adherence rates in the 
pre-adolescent and adolescent population. According to the CDC, 63% of teen girls and 50% 
of teen boys in the U.S. have started the HPV vaccine series by having received one dose of 
the two required doses for completing the series (Centers for Disease Control and Prevention, 
2017). Kentucky rates for the first HPV vaccination in 2015 for females were 57.4% and 
males were 34.8% (Reagan-Steiner, Yankey, Jeyarjah, Elam-Evans, Curtis, MacNeil, 
Markowitz & Singleton, 2016). Healthy People 2020, lists a goal of HPV vaccination rates in 
both females and males to a target of 80% (Healthy People 2020, 2017). Compared to the 
uptake of other vaccinations recommended at the same age, the percentage of those reveiving 
the HPV vaccination is comparatively low. Eighty-six percent of teens received Tetanus, 
di[theria and pertusis (Tdap) and eighty one percent received the meningococcal vaccine 
(Centers for Disease Control and Prevention, 2017).  If an 80% rate of adolescent HPV 
vaccination is accomplished that could potentially prevent 53,000 or more cases of cervical 
cancer and other cancers related to HPV (Gable, Eder, Noonan, & Feemster, 2016). It is 
apparent that there is room to improve the HPV percentages as Tdap and meningococcal 
vaccines are recommended around the same time the HPV vaccine series should begin.  
 There are many reasons that contribute to low vaccination rates including parental 
hesitancy, provider practices, and vaccine accessibility (Gable, Eder, Noonan, & Feemster, 
2016). The CDC released new guidelines in 2016 that recommend children as young as 9 
years old and up to their 15th birthday can receive two doses of the HPV vaccine at least six 
months apart rather than the three doses that were previously recommended (CDC, 2016). It 
was determined by available immunogenicity evidence that two doses given 6-12 months 
apart will provide equivalent efficacy to three doses if initiated and completed before the 
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child turns 15 years old (Meites, Kempe, & Markowitz, 2016). The change to the 
recommendation provides effective and lasting protection for adolescents while having the 
potential to increase coverage rates. 
 Lack of primary care healthcare providers fully supporting and encouraging the HPV 
vaccine is a barrier in developing better uptake of the HPV vaccination (Gable, Eder, 
Noonan, & Feemster, 2016). Strong provider recommendations to the HPV vaccine can 
reflect up to a 5-fold increase of decisions made by parents to have their child vaccinated 
(American Academny of American Physicians, 2017). There is some resistance from parents, 
but most depend on advice given from the provider (Gable, Eder, Noonan, & Feemster, 
2016). Evaluation of vaccination rates in primary care practices is needed to better determine 
status of HPV vaccination in a select patient population and purpose methods of intervention 
to increase HPV vaccination rates.  
Purpose 
 The purpose of this study was to identify current HPV vaccination rates at a 
pediatric primary care clinic in Kentucky and to evaluate pediatric primary care provider 
perspectives of the barriers and facilitators for the HPV vaccine for children ages 11-14. 
Learning more about the facilitators and barriers of HPV vaccinations can help guide 
recommendations to the participating clinic with a goal to increase completion rates. This 
study will examine pediatric primary care providers’ opinions, facilitators and barriers to the 
HPV vaccination in children ages 11 to 14. Determining current rates and receiving feedback 
of providers perceptions will be a factor in determining what can help increase HPV 
vaccination adherence in their healthcare setting.  
 Initial objectives for this project included the following: 
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• Identify self-reported barriers and facilitators among pediatric primary care 
providers for administering and completing HPV vaccination series in children 11-
14 years old.  
• Identify and compare HPV rates of a Kentucky pediatric primary care office to 
national rates, Kentucky rates and Healthy People 2020 goals 
Methods 
Procedure and Sample 
This project included sending out a survey to providers in a pediatric primary clinic in the 
Southeastern United States that included qualitative and quantitative questions with additional 
options for opinions and comments. This project also included a retrospective chart review at the 
same pediatric primary care clinic. This charts that met inclusion criteria were reviewed for 
reviewed for: age, gender, ethnicity, insurance type, provider type responsible for the visit, 
number of HPV vaccine doses, HPV vaccination dates, dates of other vaccinations common for 
the age range, and if there was a refusal for the HPV vaccination. 
The retrospective chart review was completed by randomly selecting 100 patient charts.  
The retrospective medical record review sample was obtained by using ICD-10 codes and CPT 
codes which identified well child visits through Allscripts AEHR. The review took take place in 
a Southeastern United States pediatric primary care clinic. Inclusion criteria included: ages 11 to 
14 at the time of the well-child visit, and must have documentation of the well child visit in the 
electronic medical record between the dates of October 1, 2016 and October 31, 2017. The 
medical records were reviewed for: age, gender, ethnicity, insurance type, provider type 
responsible for the visit, number of HPV vaccine doses, HPV vaccination dates, dates of other 
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vaccinations common for the age range such as Tdap and meningococcal, and if there was a 
refusal for the HPV vaccination. 
The instrument used to carry out the survey portion of the study was modified from its 
original version with permission from the project director for the study Human Papillomavirus 
(HPV) Vaccination in Kentucky: An Environmental (Appendix A) and was administered using 
Qualtrics. The survey included 24 questions and took about 15 minutes to complete. The 
participants of the survey consented to take the survey and reserved the right to not answer 
questions they did not wish. Answers to the survey were anonymous and names did not appear or 
were used on research documents or in presentations or publications. The survey was open for 4 
weeks and sent out by a designated employee of the clinic via email through the clinic listserv 
and a reminder email was sent two weeks later before the survey ended. All	  providers	  at	  the	  clinic	  (including	  physicians	  and	  nurse	  practitioners)	  were	  invited	  to	  participate	  in	  an	  online	  survey.	  	  The	  survey	  was	  disseminated	  via	  a	  link	  that	  was	  emailed	  to	  providers	  and	  generated	  by	  Qualtrics.	  Inclusion	  criteria	  included	  the	  ability	  to	  read	  and	  write	  English	  and	  a	  pediatric	  primary	  care	  provider	  in	  the	  setting	  where	  the	  study	  was	  conducted. The	  total	  sample	  from	  the	  retrospective	  chart	  review	  included	  100	  adolescents	  between	  the	  ages	  11-­‐14	  who	  were	  eligible	  for	  the	  HPV	  vaccine	  and	  visiting	  for	  a	  well	  child	  exam.	  Random	  sampling	  was	  used	  to	  determine	  the	  100	  charts	  that	  would	  be	  used	  for	  the	  review.	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Data collection 
 Approval was obtained from the Medical Institutional Review Board (IRB) of the 
University of Kentucky. The retrospective chart review data from well child medical records 
were from visit dates between October 1 2016 and October 31, 2017. 
 The survey for this project was administered by Qualtrics and an anonymous link was 
included on the email invitation that was sent out to providers. The email that included the 
anonymous link was sent to providers by a designated clinic employee to ensure the PI would not 
have contact with the participants.  To protect against breaches in confidentiality and invasion of 
privacy for the providers there was no questions asked that could identify individuals.   
Data Analysis 
Data analysis was conducted using IBM Statistical Software Analysis Package (SPSS) 
and the Statistical Analysis Software (SAS) System. Descriptive statistics were used to 
summarize the demographic characteristics of the study sample for the chart review and the 
survey sample. Varriations in vaccines rates based on demographic characteristics were 
examined. Major themes were summarized for the responses to the open-ended questions 
regarding barriers and facilitators of initiation and completion of HPV vaccinations.  
 
Results 
Retrospective Chart Review In	  the	  total	  sample	  (Table	  1)	  the	  average	  age	  of	  patients	  was	  12.8	  years	  (SD	  1.3).	  Slightly	  more	  than	  half	  were	  male	  (53%)	  and	  the	  rest	  were	  female	  (47%).	  Majority	  of	  the	  patients	  were	  white	  (48.5%)	  followed	  by	  African	  American	  (35.4%),	  Asian	  (15.2%),	  Hispanic	  (15.2%)	  and	  unreported	  (1%).	  Patients	  were	  mostly	  insured	  by	  the	  government	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(67%)	  then	  followed	  by	  private	  insurance	  (29%)	  and	  uninsured	  (4%).	  At	  the	  pediatric	  primary	  care	  clinic	  56%	  of	  patients	  received	  their	  Tdap	  and	  did	  not	  receive	  the	  first	  dose	  of	  the	  HPV	  series.	  	  However,	  for	  those	  patients	  that	  received	  the	  Tdap	  and	  not	  the	  first	  dose	  of	  the	  HPV	  series	  45%	  had	  documentation	  of	  the	  refusal.	  Total	  compliance	  for	  patients	  who	  were	  due	  for	  their	  second	  HPV	  vaccine	  was	  18.6%	  with	  11	  of	  59	  patients	  completing	  their	  series	  and	  6	  of	  them	  were	  not	  yet	  due	  for	  the	  vaccine	  but	  received	  it	  anyway.	  	  
Provider Survey 
 In the total sample (Table 2) of the survey participants (n=9)  and an estimated 53% 
response rate, the average age of providers was 52.22 years (SD=13.31) and the average time of 
the current role for providers was 15 years (SD=15.29). Majority of the participants were female 
(66.7%) followed by males (33.3%). All of the participants classified themselves as white 
(100%) and non-Hispanic (100%). Over three quarters of the respondents were physicians 
(77.8%). When asked, “What are following issues most responsible for low rates of HPV 
vaccination among females 11-14 in your healthcare setting?” all participants answered, “ Parent 
perception that there is no need to vaccinate girls who are no sexually active.” However, when 
asked the same question about males the participants answered, “that boys are at low risk for 
HPV-related cancers” (88.89%) and “parent belief that girls and women should be the ones to 
take preventative steps against HPV-related diseases such as cervical cancer” (11.11%). The 
majority of the providers said that they start recommending patients initiate the HPV vaccine 
series at age 11-12 years (77.8%). When asked about their estimation of “what percentage of 
HPV vaccination eligible patients ages 11-14 in your clinic have completed the 2-dose series?” 
majority of providers responded with 25%-50% (55.6%), followed by between 51%-75% 
(22.2%), between 76%-100% (11.1%) and one respondent was undetermined.  
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 There were a number of questions that were select all that apply and are described in the 
next paragraph. When asked “how do you present the HPV vaccine when it is offered” (Table 3) 
8 responders (30.8%) chose “as a vaccine that prevents HPV cancer,” 6 responders (23.1%) 
chose “As a vaccine that is part of the adolescent platform of vaccinations,” 4 responders 
(15.4%) chose “as a vaccine that is due,” 3 responders (11.5%) chose “as an optional vaccine,” 2 
responders (7.7%) chose as a vaccine that prevents STIs/STDs,” and 3 responders (11.5%) chose 
“other, please specify,” and provided a response. Providers were asked about facilitators and 
barriers to promoting the vaccine and their answers and percentages are described below in Table 
4 and 5. When asked, “what are the most common reasons for HPV vaccine refusal in your 
healthcare setting?” 26.7% of providers chose “unwillingness to add a vaccine that isn’t required 
to immunization schedule,” 20% chose “concerns about the vaccine’s safety,” 20% chose “belief 
that the child is too young,” 20% chose lack of knowledge about HPV related diseases and 13% 
chose “fear of riskier sexual behaviors/early initiation of sexual activity.” Fifty percent of 
providers responded that they provide educational materials for patients and parents to review 
when they have vaccine refusals for HPV and 38.9% stated that they document and make 
vaccine recommendation at the next visit. And finally, when asked if “your practice or clinic 
uses any particular methods of recall or reminders to improve HPV vaccination series 
completion,” 33.3% answered that they use phone call reminders, 33.3% answered no, 8.3% 
answered mailing of reminder cards, and 25% responded with other and supplied a response. 
The themes of the open response questions were summarized and the following themes 
were most common: optional vaccine, time restraints, parental knowledge, staff education, and 
misconceptions. Providers provided some insight into the barriers by responding to open ended 
questions within the survey. Some of the comments they made about barriers for HPV vaccines 
HPV	  VACCINES	  IN	  CHILDREN	  	   	   	  	  
	   15	  
included one provider saying “we are a teaching clinic so nurses, medical students, and residents 
are often the front line in contact with the patients before the attendings see the patients. If 
misinformation or a weak recommendation is given before we go in, it makes it a little harder to 
get patients to agree” and multiple providers mentioning time constraints.  
Providers also made some strong comments about the facilitators for HPV vaccines in 
their clinic including one provider mentioning “We have nurses and providers that feel strongly 
about giving the vaccine. We have good educational information/handouts/resources provided by 
our vaccine reps and online that help our recommendation.” 
Provider recommendations for HPV vaccines within the clinic included some great 
insight including “we are working on educating the nurses, med students, residents, and 
attendings on the importance of the vaccine, what it prevents, how it is more effective when 
given at a younger age, and how to present it in the middle of the other required vaccines at that 
visit so that it’s importance is stressed,” as well as “make sure that nursing staff across the board 
is telling parents about the vaccine when they work the patient up.” 
Discussion 
HPV vaccine rates have risen within the last decade, but there is still some improvement 
needed to meet the goal rates of Healthy People 2020. Also, the gap of rates between males and 
females are narrowing demonstrated by a six-percentage increase in males between 2015 and 
2016 (Centers for Disease Control and Prevention, 2018). This study aimed to identify barriers 
and facilitators of the HPV vaccine and to evaluate HPV vaccination rates a single clinic. There 
is evidence that discusses how provider recommendations play a big role for parental decisions 
about HPV vaccines. Overall, this project demonstrated similar results to what is reported by the 
CDC, which states that 43.3% of adolescents are up to date with their HPV vaccination series 
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(Walker et al, 2017).  Providers gave insight into important perspectives about barriers and 
facilitators associated with initiating and completing the HPV series. The coverage of the 
initiation (at least one dose) of the HPV series remains 22-28% lower than the other 
immunizations that are given at the ages of 11-12 and identifies that there is opportunity for 
improving practices (Walker et al, 2017). Data from the survey provided more insight into the 
underestimation providers have of the affects of their recommendations on parental decisions 
about the HPV vaccine. Putting the focus on providers could be beneficial because they do play a 
huge role in vaccinations. The results from this study were similar to findings in other studies 
that discovered a high number of missed opportunities for HPV vaccinations. By	  following	  the	  new	  guidelines	  there	  will	  hopefully	  be	  an	  increase	  in	  the	  number	  of	  completion	  rates	  for	  the	  HPV	  vaccine.	  After the addition of the new guideline, there was a 6.3% higher national rate 
than the 3 dose series when the new guidelines were applied retrospectively.  Findings from this 
study also suggest that there are some opportunities that could be changed and potentially 
increase the initiation and completion rates for the HPV vaccine.	  
Limitations 
 This project has several limitations. This study was performed at a single pediatric 
primary care clinic therefore the findings cannot be generalized to larger populations. The time 
constraints of the study limited data collection. The sample from the provider survey was small 
so results should be interpreted with this in mind. Also, the study sample of the chart review was 
performed retrospectively and there is no way to ensure patient information was entered into the 
medical record correctly or there were not data omissions.  
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Implications for Practice 
 When	  collecting	  data	  some	  things	  that	  were	  noticed	  is	  providers	  were	  recommending	  the	  HPV	  vaccine	  in	  different	  ways,	  at	  different	  times	  and	  from	  different	  people.	  While	  this	  is	  not	  wrong,	  there	  are	  more	  than	  one	  way	  but	  it	  should	  be	  consistent.	  These	  vaccinations	  should	  be	  recommended	  the	  same	  way	  at	  every	  visit	  for	  children	  that	  are	  eligible.	  We	  cannot	  control	  what	  patients	  or	  parents	  choose,	  but	  increasing	  the	  expectations	  of	  presenting	  the	  HPV	  vaccination	  could	  help	  increase	  rates.	  High	  HPV	  vaccination	  coverage	  is	  possible	  in	  the	  United	  States.	  My	  recommendation	  for	  this	  clinic	  is	  to	  incorporate	  a	  policy	  practice	  change	  within	  the	  clinic	  to	  make	  a	  tailored	  intervention	  and	  to	  establish	  an	  appropriate	  time	  to	  re-­‐evaluate	  this	  intervention.	  Some	  ideas	  would	  be	  to	  create	  a	  universal	  presentation	  of	  vaccines	  that	  present	  HPV	  vaccines	  as	  a	  cancer	  prevention	  vaccine	  recommended	  by	  the	  CDC	  (Centers	  for	  Disease	  Control	  and	  Prevention,	  2018).	  	   According	  to	  the	  literature	  there	  are	  many	  different	  interventions	  that	  have	  been	  successful	  for	  HPV	  vaccination	  challenges.	  Some	  ways	  this	  could	  be	  achieved	  is	  by	  taking	  advantage	  of	  every	  health-­‐care	  encounter,	  including	  acute-­‐care	  visits,	  to	  assess	  every	  adolescent’s	  vaccination	  status	  can	  help	  minimize	  missed	  opportunities	  (Centers	  for	  Disease	  Control	  and	  Prevention,	  2018).	  Potential	  strategies	  include	  using	  vaccination	  prompts	  available	  through	  electronic	  health	  records	  or	  checking	  local	  and	  state	  immunization	  information	  systems	  to	  assess	  vaccination	  needs	  at	  every	  encounter	  (Centers	  for	  Disease	  Control	  and	  Prevention,	  2018).	  Series	  completion	  also	  can	  be	  promoted	  through	  scheduling	  appointments	  for	  their	  next	  doses	  before	  patients	  leave	  providers’	  offices	  after	  receipt	  of	  their	  first	  HPV	  vaccine	  doses	  and	  with	  automated	  reminder-­‐recall	  or	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text	  messaging	  systems	  (Centers	  for	  Disease	  Control	  and	  Prevention,	  2018).	  My	  study	  findings	  identified	  that	  providers	  used	  different	  methods	  to	  remind	  patients	  of	  their	  next	  visit	  or	  vaccine	  and	  this	  should	  be	  done	  the	  same	  way	  consistently	  with	  all	  providers.	  	   One	  of	  the	  recommendations	  made	  by	  the	  American	  Academy	  of	  Pediatrics	  is	  to	  distinguish	  a	  HPV	  champion	  within	  the	  office.	  The	  responsibility	  of	  the	  HPV	  champion	  is	  to	  be	  a	  resource	  for	  healthcare	  provider	  education	  and	  provide	  changes	  that	  can	  be	  made	  in	  practice	  to	  help	  improve	  vaccination	  rates.	  One	  of	  recommended	  changes	  is	  to	  incorporate	  a	  daily	  huddle	  at	  the	  beginning	  of	  the	  day	  to	  incorporate	  immunization	  planning.	  Having	  a	  designated	  staff	  member	  to	  serve	  as	  a	  vaccine	  coordinator	  will	  have	  dedicated	  time	  to	  review	  the	  next	  day’s	  patients	  to	  identify	  any	  missing	  immunizations.	  During	  the	  huddle	  a	  list	  of	  patients	  and	  immunizations	  needed	  should	  be	  listed	  for	  the	  day.	  	  	   It	  is	  important	  to	  make	  sure	  that	  all	  clinic	  staff,	  including	  those	  answering	  the	  phone	  and	  making	  appointments,	  are	  communicating	  the	  same	  way	  about	  HPV	  vaccine.	  Put	  the	  focus	  on	  cancer	  prevention	  and	  provide	  talking	  points	  for	  the	  staff.	  The	  CDC	  offers	  tips	  sheets	  for	  conversations	  and	  addressing	  the	  HPV	  vaccine	  that	  could	  be	  shared	  with	  everyone	  in	  the	  clinic	  and	  those	  entering	  the	  clinic	  to	  ensure	  universal	  conversations	  and	  recommendations.	  As	  evidenced	  from	  the	  study,	  providers	  and	  nursing	  feel	  strongly	  about	  the	  HPV	  vaccine	  and	  providers	  talk	  about	  nursing	  doing	  great	  with	  how	  they	  talk	  with	  patients,	  but	  should	  be	  done	  universally.	  	  Further research is needed to assess if an 
intervention would be beneficial to the clinic at a later date. This study demonstrated provider 
opinions of barriers and facilitators to the HPV vaccine and HPV rates at the clinic, however, it 
does not measure a change of use into practice. Future	  studies	  should	  consider	  doing	  something	  similar	  to	  what	  I	  did	  and	  implementing	  a	  tailored	  intervention	  within	  the	  same	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clinic	  to	  measure	  HPV	  rates	  before	  and	  after	  the	  implementation	  by	  doing	  a	  retrospective	  chart	  review.	  This	  would	  be	  a	  great	  opportunity	  for	  future	  DNP	  students	  as	  a	  QI	  project.	  
Conclusion 
 Providers	  provided	  important	  perspectives	  about	  barriers	  and	  facilitators	  associated	  with	  initiating	  and	  completing	  the	  HPV	  series.	  As	  evidenced	  from	  their	  survey,	  majority	  of	  providers	  recommend	  HPV	  vaccination	  starting	  at	  ages	  11-­‐12	  and	  find	  parental	  resistance	  and	  the	  fact	  that	  they	  do	  not	  “have”	  to	  get	  the	  HPV	  vaccine	  a	  main	  barrier	  to	  initiation	  and	  completion	  of	  the	  HPV	  series.	  The	  CDC,	  mentions	  that	  “parents	  trust	  providers	  opinions	  more	  than	  anyone	  else’s	  when	  it	  comes	  to	  immunizations”	  and	  this	  is	  important	  for	  providers	  to	  remember	  so	  they	  don’t	  underestimate	  their	  role	  in	  vaccination	  rates.	  	  Also,	  as	  evidenced	  from	  the	  survey	  providers	  felt	  that	  they	  have	  good	  resources	  and	  educations	  materials	  and	  can	  still	  receive	  refusals.	  It	  is	  great	  that	  providers	  feel	  they	  have	  support	  for	  obtaining	  resources	  and	  to	  support	  their	  recommendations	  of	  HPV	  vaccine	  to	  families.	  	  A	  Future	  QI	  project	  should	  consider	  implementing	  an	  intervention	  within	  the	  same	  clinic	  with	  a	  goal	  of	  improving	  vaccination	  rates	  based	  upon	  the	  needs	  of	  the	  clinic.	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Table 1. Demographic and clinical characteristics of the study sample (N = 100) 
 
Demographic and clinical characteristic Mean (SD) or n (%) 
Age (years) 12.8 (1.3) 
Gender 
   Female 
   Male 
 
47 (47%) 
53 (53%) 
Race 
   White 
   Black 
   Asian 
   Unreported 
 
48 (48.5%) 
35 (35.4%) 
15 (15.2%) 
1 (1.0%) 
Hispanic 
   Yes 
   No 
 
15 (15.2%) 
84 (84.8%) 
Insurance 
  Medicare 
  Medicaid 
  Private 
  Uninsured 
 
0 (0%) 
67 (67.0%) 
29 (29.0%) 
4 (4.0%) 
HPV Number of Doses 
  0 
  1 
  2 
  3 
 
41 (41.0%) 
31 (31.0%) 
19 (19.0%) 
9 (9.0%) 
Provider type seeing patient 
  Nurse Practitioner 
  Physician Assistant 
  Physician 
  Resident Physician 
 
58 (58%) 
6 (6.0%) 
20 (20%) 
16 (16%) 	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Table 2. Survey demographics and characteristics (N= 9) 
 
Demographic and clinical characteristic Mean (SD) or n (%) 
Age (years) 52.22 (13.31) 
Years in current provider role 15 (15.29) 
Gender 
   Female 
   Male 
 
6 (66.7%) 
3 (33.3%) 
Race 
   White 
 
 
9 (100%) 
 
Hispanic 
   Yes 
   No* 
 
0 (0%) 
8 (100%) 
Provider type seeing patient 
  Nurse Practitioner 
  Physician Assistant 
  Physician 
  Resident Physician 
 
2 (22.2%) 
7 (77.8%) 
0 (0%) 
0 (0%) 
*Note, one person decided not to answer this question 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
HPV	  VACCINES	  IN	  CHILDREN	  	   	   	  	  
	   24	  
Table	  3.	  Frequency	  of	  how	  providers	  present	  HPV	  vaccine	  	   How	  do	  you	  present	  the	  HPV	  vaccine	  when	  it	  is	  offered?	  (Select	  all	  that	  apply)*	  	   Frequency	  (n)	   Percent	  (%)	  As	  an	  ‘optional’	  vaccine	   3	   11.54	  As	  a	  vaccine	  that	  is	  due	   4	   15.38	  As	  a	  vaccine	  that	  prevents	  STIs/STDs	   2	   7.69	  As	  a	  vaccine	  that	  is	  part	  of	  the	  adolescent	  platform	  of	  vaccinations	  (tetanus,	  diphtheria,	  and	  pertussis	  (Tdap),	  meningococcal,	  annual	  influenza,	  etc)	  
6	   23.08	  
As	  a	  vaccine	  that	  prevents	  HPV	  cancer	   8	   30.77	  Other,	  please	  specify*	   3	   11.54	  *Note,	  open	  response	  questions	  were	  coded	  and	  themes	  were	  analyzed	  *Note,	  the	  participants	  were	  allowed	  to	  pick	  more	  than	  one	  answer	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Table	  4.	  Frequency	  of	  barriers	  to	  the	  HPV	  vaccine	  	  Which	  of	  the	  following	  are	  barriers	  in	  your	  healthcare	  setting	  to	  providing	  the	  HPV	  vaccine?	  (Select	  all	  that	  apply)*	  	  	   Frequency	  (n)	   Percent	  (%)	  The	  cost	  of	  the	  vaccine	  in	  your	  healthcare	  setting	   0	   0	  The	  time	  it	  takes	  to	  discuss	  the	  HPV	  vaccination	  during	  an	  office	  visit	   1	   12.5	  Healthcare	  provider	  concern	  about	  the	  vaccine’s	  safety	   0	   0	  Keeping	  the	  vaccine	  in	  stock	  in	  the	  healthcare	  setting	   1	   12.5	  Storing	  the	  vaccine	  (e.g.	  refrigeration,	  space)	   1	   12.5	  Other,	  please	  specify*	   5	   62.5	  *Note,	  open	  response	  questions	  were	  coded	  and	  themes	  were	  analyzed	  *Note,	  the	  participants	  were	  allowed	  to	  pick	  more	  than	  one	  answer	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  Table	  5.	  Frequency	  of	  facilitators	  to	  the	  HPV	  vaccine	  	   Which	  of	  the	  following	  are	  facilitators	  in	  your	  healthcare	  setting	  to	  providing	  the	  HPV	  vaccine?	  (Select	  all	  that	  apply)*	  	   Frequency	  (n)	   Percent	  (%)	  Support	  and	  training	  from	  professional	  organization(s)	   4	   23.53	  Vaccine	  for	  Children	  (VFC)	  program	  participation	   8	   47.06	  Community	  support	  of	  HPV	  vaccine	   3	   17.65	  Other,	  please	  specify*	   2	   11.76	  *Note,	  open	  response	  questions	  were	  coded	  and	  themes	  were	  analyzed	  *Note,	  the	  participants	  were	  allowed	  to	  pick	  more	  than	  one	  answer	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Appendix A 
 
Provider Survey 
 
1. Are you a Pediatric Primary Care Provider? 
£ Yes 
£ No  
 
2. What is your role in your practice setting? 
£ Nurse Practitioner 
£ Physician  
£ Physician Assistant 
£ Resident Physician 
 
3. How many years have you been in your current role? 
£ ________ 
 
4. What is your gender? 
£ Female 
£ Male 
£ Other 
 
5. What is your age in years? 
£ _________ 
 
6. Please specify your race. 
£ White or Caucasian 
£ Black or African American 
£ Asian 
£ American Indian/Alaska Native 
£ Native Hawaiian or Other Pacific Islander 
£ Other, please specify_________ 
 
7. Please specify your ethnicity. 
£ Hispanic  
£ Non-Hispanic 
£ Other, please specify__________ 
 
8. In 2016, the HPV vaccine completion rate for adolescent females in Kentucky was 39.7% 
compared to the US rate of 49.5%. In your opinion, which of the following issues are 
most responsible for the low rates of HPV vaccination among females 11 to 14 in your 
healthcare setting? 
£ Perceived low risk for cervical and other HPV-related cancers 
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£ Parent perception that girls are at low risk for genital warts 
£ Parent perception that there is no need to vaccinate girls who are not sexually 
active 
 
9. What are other reasons for the low rates of HPV vaccination among females 11 to 14?  
 
10. In 2016, the HPV vaccine completion rate for adolescent males in Kentucky was 28.5% 
compared to the US rate of 37.5%. In your opinion, which of the following issues are 
most responsible for the low rates of HPV vaccination among males 11 to 14 in your 
healthcare setting? 
£ That boys are at low risk for HPV-related cancers 
£ Parent perception that boys are at low risk for genital warts 
£ Parent belief that girls and women should be the ones to take preventative steps 
against HPV-related diseases such as cervical cancer 
 
11.  What are other reasons for the low rates of HPV vaccination among males 11 to 14?  
 
12. At what age do you start recommending patients initiate the HPV vaccine series? 
£ 9-10 years old 
£ 11-12 years old  
£ 13-14 years old 
£ 14+ years old 
 
13. How do you present the HPV vaccine when it is offered? (Select all that apply) 
£ As an ‘optional’ vaccine  
£ As a vaccine that is due 
£ As a vaccine that prevents STIs/STDs 
£ As a vaccine that is part of the adolescent platform of vaccinations (tetanus, 
diphtheria, and pertussis [Tdap], meningococcal, annual influenza, etc.) 
£ As a vaccine that prevents HPV cancer 
£ Other please specify________ 
 
14. Which of the following are barriers in your healthcare setting to providing the HPV 
vaccine? (Select all that apply)  
£ The cost of the vaccine in your healthcare setting 
£ The time it takes to discuss the HPV vaccination during an office visit  
£ Healthcare provider concern about the vaccine’s safety  
£ Keeping the vaccine in stock in the healthcare setting 
£ Storing the vaccine (e.g. refrigeration, space) 
£ Other, please specify________ 
 
15. Which of the following are facilitators in your healthcare setting to providing the HPV 
vaccine? (Select all that apply) 
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£ Support and training from professional organization(s) 
£ Vaccines for Children (VFC) program participation 
£ Community support of HPV vaccine 
£ Other, please specify___________ 
 
16. Which of the following are barriers to you promoting the vaccine? (Select all that apply) 
£ Difficulty discussing sexual health with patients/parents  
£ Concern that patients will not complete the HPV vaccine series 
£ I’m not prepared to discuss the vaccine or HPV-related diseases  
£ My staff and I are not adequately trained on the vaccine or HPV-related diseases 
£ Other, please specify_________ 
£ None, I have no barriers 
 
17. What are the most common reasons for HPV vaccine refusal in your healthcare setting? 
(Select all that apply) 
£ Inadequate insurance coverage/Inability to pay 
£ Lack of knowledge about HPV-related diseases 
£ Concerns about the vaccine’s safety  
£ Unwillingness to add a vaccine that isn’t required to immunization schedule 
£ Fear of riskier sexual behaviors/early initiation of sexual activity 
£ Belief that child is too young to be vaccinated 
£ Other, please specify_______ 
 
18. How do you respond to HPV vaccine refusal? (Select all that apply) 
£ Document and do not recommend 
£ Document and make vaccine recommendation at next visit 
£ Provide educational materials for patient/parents to review 
£ Other, please specify_________ 
 
19. Does your practice or clinic use any particular methods of recall or reminders to improve 
HPV vaccination series completion (i.e., 2 doses)? (Select all that apply) 
£ Yes, mailed reminder cards 
£ Yes, text reminders 
£ Yes, phone call reminders 
£ Yes, other method 
£ No 
£ Other, please specify__________ 
 
20. In your estimation, what percentage of HPV vaccination-eligible patients ages 11 to 14 in 
your clinic have completed the 2-dose series? 
o Less than 25% 
£ Between 25%-50% 
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£ Between 51%-75% 
£ Between 76%-100% 
£ Unable to determine  
 
21.  Describe the barriers in your health care setting that impact HPV vaccination: 
 
22. Describe the facilitators in your health care setting that impact HPV vaccination: 
 
23. What changes would you recommend in your health care setting to help eliminate 
barriers to HPV vaccination and increase HPV vaccination rates: 
 
 
*This survey was modified from the original version in which permission was provided from the original 
authors and study: Wilburn, A., Vanderpool, R., Knight, J., & Ever, M. Human Papillomavirus (HPV) 
Vaccination in Kentucky: An Environmental Scan. Markey Cancer Center and College of Public Health. 	   	  	  	  	   	  
 
